The health system defended itself by claiming it had done nothing wrong, and that Dr T had a clear duty to inform it of the ...

Skysona is indicated to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy.

The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Applied Therapeutics regarding the New Drug Application (NDA) for govorestat for the treatment of classic ...

The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

According to the Company, the premixed bags were developed to reduce preparation time and the risk of preparation errors.

Aficamten is a small molecule cardiac myosin inhibitor designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle.

More than 7 million Americans struggling with obesity would become eligible for coverage under the proposed change ...

(HealthDay News) — Antibiotic treatment for 7 days is noninferior to 14 days for hospitalized patients with bloodstream infection, according to a study published online Nov. 20 in the New England ...

Tiragolumab is a novel immune checkpoint inhibitor that binds to TIGIT, a protein receptor on immune cells, which suppresses ...

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks ...

The approval was based on data from 5 randomized, double-blind, placebo-controlled trials that included 317 patients with supraventricular tachycardia.

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for vutrisiran for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM).